Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) Operating Expenses: 2021-2022

Historic Operating Expenses for Cardiol Therapeutics (CRDL) over the last 2 years, with Sep 2022 value amounting to $10.1 million.

  • Cardiol Therapeutics' Operating Expenses rose 25.54% to $10.1 million in Q3 2022 from the same period last year, while for Sep 2022 it was $36.7 million, marking a year-over-year change of. This contributed to the annual value of $30.9 million for FY2021, which is 100.17% up from last year.
  • According to the latest figures from Q3 2022, Cardiol Therapeutics' Operating Expenses is $10.1 million, which was up 39.98% from $7.2 million recorded in Q2 2022.
  • Over the past 5 years, Cardiol Therapeutics' Operating Expenses peaked at $10.4 million during Q4 2021, and registered a low of $5.3 million during Q2 2021.
  • For the 2-year period, Cardiol Therapeutics' Operating Expenses averaged around $8.2 million, with its median value being $8.1 million (2021).
  • Data for Cardiol Therapeutics' Operating Expenses shows a peak YoY skyrocketed of 36.89% (in 2022) over the last 5 years.
  • Over the past 2 years, Cardiol Therapeutics' Operating Expenses (Quarterly) stood at $10.4 million in 2021, then rose by 25.54% to $10.1 million in 2022.
  • Its Operating Expenses was $10.1 million in Q3 2022, compared to $7.2 million in Q2 2022 and $9.0 million in Q1 2022.